Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CAR-T therapy for multiple sclerosis enters US trials for first time

Hopes are high that engineered immune cells, which are already in use to treat blood cancer, will halt the progression of a degenerative autoimmune disorder.
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed  Google Scholar

The first US trials of engineered cells to treat multiple sclerosis have started recruiting volunteers, raising hopes for a new therapeutic option for this devastating neurodegenerative disease and other autoimmune disorders.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-024-00470-5

Updates & Corrections

  • Correction 22 February 2024: An earlier version of this article incorrectly described the phase of a clinical trial run by Bristol Myers Squibb. This has now been corrected.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links